Previous studies have identified PIK3CA mutation in 10.3–37.5% of the HER2-positive breast cancer cases [23]–[26] and p53 mutations in 18%–25% of primary breast carcinomas [27]. This evidence concerns the gene ERBB2 and breast carcinoma.